ALN-HBV

N/A

Report date: 2025/03/18 14:31:24
NME

Base Information

Drug NameALN-HBV
Drug Alias NameALN-HBV
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceAsialoglycoprotein receptor modulators
TargetsAsialoglycoprotein receptor
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingaporeNew ZealandAustralia +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHepatitis B, ChronicHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A